Clinical Studies

Breast Care
Cardiology
Colon Cancer
Dermatology
Diabetes
Gastrointestinal
HIV/AIDS
Mental Health
Neurology
NeuroOphthalmology
Obesity/Weight Management
Women's Health
Other


Special Features
Advances/Research

 

Treatment of Diabetes After Gastric Bypass Surgery with Sitagliptin

Principal Investigator:   Blandine Laferrere., MD
Time frame of study:   Ongoing
Time frame of participation   Six weeks
Location of Study:   New York Obesity Nutrition Research Center, Mount Sinai St. Luke's 1111 Amsterdam Avenur at 114th Street, New York, NY 10025
Contact name, number and email  

Margaret Sala at 212.523.3503 or msala@chpnet.org or Carolina Espinosa at 212.523.3581 or cespinosa@chpnet.org


Purpose of Study:
Analyze the effect of sitagliptin (Januvia®), an FDA approved medication, for the treatment of type 2 diabetes in patients after gastric bypass surgery

Summary:

  • Two  half day research visits and two 1-hour research visits over 6-8 weeks
  • Participants either take sitagliptin (Januvia®) or a placebo pill for 4-6 weeks
  • Day 1: Initial Screening
  • Day 2: A 4- hour Meal test with IV
  • Day 3: Midway Check-In Appointment for questionnaires (about 1 hour)
  • Day 4: A second 4-hour meal test  with IV

Criteria for Participation:

  • Had Gastric Bypass Surgery at least  1 year ago, and was diagnosed with type 2 diabetes before gastric bypass surgery
  • With current Hba1c> 6.4% and/or fasting blood glucose (sugar) > 125 mg/dl
  • Able and willing to check glucose by finger sticks

 

Benefits/Compensation:

Learn about your diabetes status, see whether the medication could be of any benefit to treat diabetes, and get nutritional and diabetes education and materials. $300 in compensation.